Calcitonin Salmon Dosing & Reconstitution Guide

Calcitonin Salmon can be administered via intranasal spray or through subcutaneous/intramuscular injection, with the route selected based on the indication. Research indicates that for osteoporosis, the nasal spray is typically utilized at a dose of 200 IU/day, delivered as one spray in alternating nostrils. For Paget's disease, studies suggest an injection frequency of daily or every other day, with a dose range of 50-100 IU/day. In cases of hypercalcemia, injections may be given every 6-12 hours at a dosage of 4-8 IU/kg. These dosing regimens highlight the variability in administration frequency and dose, underscoring the necessity for careful adherence to research protocols to optimize outcomes.

The storage requirements for Calcitonin Salmon vary between its lyophilized and reconstituted forms. Lyophilized Calcitonin Salmon should be refrigerated at temperatures between 2-8 °C (36-46 °F) to maintain stability. Once reconstituted, the nasal spray can be stored at room temperature and should be used within 35 days of opening, while the reconstituted injection form must remain refrigerated. The defined shelf life of 35 days post-reconstitution emphasizes the need for diligent inventory management in research settings to prevent the use of expired materials.

For subcutaneous and intramuscular administration of Calcitonin Salmon, various anatomical sites are recommended based on standard practices. Common injection sites include the abdomen, thigh, and upper arm for subcutaneous injections, while the gluteal muscle is typically used for intramuscular injections. The selection of injection sites is crucial for ensuring proper absorption and minimizing local discomfort. Research highlights the importance of rotating injection sites to reduce the risk of tissue irritation and enhance patient comfort during administration.

Safety profiles for Calcitonin Salmon indicate that the nasal spray formulation may lead to rhinitis in approximately 12% of users, alongside other nasal symptoms such as epistaxis, dryness, and crusting. Injection routes have been associated with nausea (10%), facial flushing (2-5%), and localized inflammation or pain at the injection site. Given the potential for allergic reactions, particularly in individuals with known sensitivities to salmon protein, skin testing may be advisable prior to initiation of treatment. Contraindications include a known hypersensitivity to Calcitonin Salmon or salmon protein, as well as pregnancy, classified as Category C. These considerations underscore the importance of thorough patient evaluation prior to administration.